Atom Therapeutics Co., Ltd.

杭州新元素药业股份有限公司

Develops ABP-671, a next-generation URAT1 inhibitor for gout, currently in Phase 2b/3 clinical trials in the US and China, with clinical data from over 900 patients across the US, China, Australia and other regions.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Overseas markets and operations
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Chapter 18A biotech